Dr. Reddy’s Laboratories announces it has launched a generic version of semaglutide injection in Canada, used for the treatment of type 2 diabetes. The company says the launch follows its receipt of a Notice of Compliance (NOC) from Health Canada on April 28, 2026. Dr. Reddy’s states it is among the first firms to introduce a generic semaglutide injection in the Canadian market, and that Canada is the first G7 country to grant market authorisation for semaglutide injection. In a company statement, Dr. Reddy’s CEO Erez Israeli links the launch to the company’s capabilities in complex drug and peptide development and says it is positioned to serve Canadian patients with “advanced, high-quality, and affordable” GLP-1 therapies. The company also says the Canada rollout builds on momentum from a recent launch in India under the brand name Obeda. Both outlets describe the Health Canada NOC date as the key trigger for the Canadian launch and characterize Dr. Reddy’s position as an early recipient/introducer of generic semaglutide in Canada.
Dr. Reddy’s launches generic semaglutide injection in Canada after Health Canada approval
Dr. Reddy’s Laboratories announces it has launched a generic version of semaglutide injection in Canada, used for the treatment of type 2 diabetes. The company says the launch follows its receipt of a...
- Dr. Reddy’s Laboratories launches a generic semaglutide injection in Canada for type 2 diabetes.
- The launch follows a Health Canada Notice of Compliance (NOC) dated April 28, 2026.
- The company says it is among the first firms to introduce generic semaglutide in the Canadian market.
- Canada is described as the first G7 country to grant market authorization for semaglutide injection.
- Dr. Reddy’s says the Canada launch builds on its India launch of semaglutide under the brand name Obeda.
The launch follows Dr. Reddy’s receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company’s readiness to serve Canadian patients Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada Canada is the first G7 country to grant market authorization for... The post Dr. Reddy’s Laboratories Launches its Generic Semaglutide Injection in Canada appeared first on Montreal Gazette.
3 months agoDr Reddy's Laboratories on Saturday said it has launched its generic version of Semaglutide injection used in treatment of type 2 diabetes in Canada. The company is among the first firms to introduce a generic Semaglutide injection in the Canadian market, following the Notice of Compliance (NOC) received from Health Canada on April 28, 2026, Dr Reddy's said in a statement. Canada is the first G7 country to grant market authorisation for Semaglutide injection, it added. "The milestone highlights our readiness to serve the Canadian patients, supported by our deep expertise in complex drug and peptide development," Dr Reddy's CEO Erez Israeli said. He further said:"With a well-established presence and strong market access capabilities in Canada, we remain committed to bringing advanced, high-quality, and affordable GLP-1 therapies closer to patients." The Canada launch builds on the momentum of the company's recent launch in India under the brand name Obeda, Israeli said. "As GLP-1
3 months ago
Procam launches HDOR “100 Days of Running” to build movement habits
Procam launches “HDOR – 100 Days of Running,” a programme designed to help people turn 100 days of movement into lasting...
SBI declares PO prelims 2026 result on sbi.bank.in; mains set for September 12
The State Bank of India (SBI) has released the Probationary Officer (PO) Prelims Result 2026 for candidates who took the...
KEA extends UGNEET/UGCET deadlines and NEET roll-number linking for Karnataka medical admissions
The Karnataka Examinations Authority (KEA) extends registration-related deadlines for UGNEET/UGCET 2026 and updates part...